Resources

In Part 1 of this Exclusive Interview, Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida to discuss the latest standards for bariatric surgery and the use of it to reverse the function of the autonomic nervous system. Aaron Vinik, MD, …

African American male, 63 years of age, type 2 diabetes, hypertension, strong family history of type 2 diabetes, hypertension and stroke. A1C is 6.7%. Blood pressure 160/96 HR 88, despite being on ACE-I and Beta Blocker.

In part 4 of this Exclusive Interview, Dr. Chous discusses his findings during a clinical trial of a multi-component supplement used to intervene in the development of diabetic retinopathy and improve visual function.

In this week's Homerun Slides, part 4 of the Canadian Diabetes Association's specific recommendations for patient-centered diabetes care.

In pancreatic beta cells, glucose metabolism is essential for the regulation of insulin secretion. Glucose is taken up by glucose transporters and metabolized to generate adenosine triphosphate (ATP), which is the main driver of glucose-induced insulin secretion (GIIS). Increased cytosolic ATP causes closure of ATP-sensitive K+ (KATP) channels, depolarizing the plasma membrane, leading to the opening of voltage-dependent Ca2+ channels (VDCCs), which allows Ca2+ influx. The resultant rise in intracellular Ca2+ concentration ([Ca2+]i) induces exocytosis of insulin granules in the triggering pathway of insulin secretion. In addition, other signals generated by glucose amplify insulin secretion. Lipid metabolism is also involved in GIIS by interacting with glucose metabolism.

We were at the ADA and AACE and have over 45 video interviews with some great information. Would you prefer to watch a video interview in its entirety, or an interview broken up into Q&A segments? Follow the link and let us know your opinion!

Diabetes screening should be protocol test in all health centers, health fairs to prevent undiagnosed diabetes and avoid later complications.

New data presented at AACE shows hypoglycemic events are less likely in patients with diabetes treated with an electronic glycemic management system.

Novo Nordisk announced positive results on its pipeline GLP-1 candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4 and 5.

In this Exclusive Interview, Dr. Joseph Aloi joins Diabetes in Control publisher Steve Freed for a discussion at the AACE 2016 convention in in Orlando, Florida, to discuss how software can help treat diabetic ketoacidosis.